购物车
- 全部删除
- 您的购物车当前为空
Top/HDAC-IN-3(Compound 31),作为一种口服活性的Topoisomerase和HDAC双重抑制剂,通过上调活性氧(ROS)水平引发DNA损伤,有效抑制癌细胞的克隆形成与迁移,同时诱导癌细胞凋亡(Apoptosis)及细胞周期阻滞。在NSCLC模型中,Top/HDAC-IN-3的抗肿瘤效果显著,其抗肿瘤效率(TGI = 77.5%,100 mg/kg)显著优于HDAC抑制剂SAHA及SAHA与拓扑异构酶抑制剂伊立替康的组合疗法。
Top/HDAC-IN-3(Compound 31),作为一种口服活性的Topoisomerase和HDAC双重抑制剂,通过上调活性氧(ROS)水平引发DNA损伤,有效抑制癌细胞的克隆形成与迁移,同时诱导癌细胞凋亡(Apoptosis)及细胞周期阻滞。在NSCLC模型中,Top/HDAC-IN-3的抗肿瘤效果显著,其抗肿瘤效率(TGI = 77.5%,100 mg/kg)显著优于HDAC抑制剂SAHA及SAHA与拓扑异构酶抑制剂伊立替康的组合疗法。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | Top/HDAC-IN-3 (Compound 31) is a dual inhibitor of Topoisomerase and HDAC with oral activity. It induces DNA damage by elevating reactive oxygen species (ROS) levels, consequently inhibiting the clonal formation and migration of cancer cells, and triggering apoptosis (Apoptosis) and cell cycle arrest. Top/HDAC-IN-3 demonstrates a significant antitumor effect in NSCLC models, exhibiting a tumor growth inhibition (TGI = 77.5%, 100 mg/kg) superior to that of the HDAC inhibitor SAHA and the combination of SAHA with the topoisomerase inhibitor Irinotecan. |
分子量 | 435.47 |
分子式 | C24H25N3O5 |
CAS No. | 3059615-90-3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容